Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics Inc (NQ: STOK )

13.03 -1.87 (-12.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 325,627
Open 14.88
Bid (Size) 5.300 (2)
Ask (Size) 14.39 (1)
Prev. Close 14.90
Today's Range 13.00 - 14.98
52wk Range 9.545 - 33.06
Shares Outstanding 39,419,313
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study
Stoke Therapeutics (NASDAQ: STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA). 
Via Benzinga

Performance

YTD
-43.37%
-43.37%
1 Month
-16.37%
-16.37%
3 Month
-2.98%
-2.98%
6 Month
-41.31%
-41.31%
1 Year
-51.85%
-51.85%

More News

Read More
Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)
From Stoke Therapeutics
Via Business Wire
7 Stocks Due for a Stunning Short Squeeze
Via InvestorPlace
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Via Benzinga
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Recap: Stoke Therapeutics Q1 Earnings
Via Benzinga
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Recap: Stoke Therapeutics Q4 Earnings
Via Benzinga
Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Via Benzinga
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
From Acadia Pharmaceuticals Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.